What Is Best for Weight Loss? A Comparative Review of the Safety and Efficacy of Bariatric Surgery Versus Glucagon-Like Peptide-1 Analogue.
Nimra Klair, Utkarsh Patel, Ayushi Saxena...
https://pubmed.ncbi.nlm.nih.gov/37905277Actively Recruiting
Age: 18Years +
FEMALE
ID06877572
Enacting Active Survivorship: Implementation of Weight Management Strategies in Endometrial Cancer Survivors
Led by University of Kansas Medical Center · Updated on 2025-10-27
50
Participants Needed
1
Research Sites
104 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This research aims to understand how doctors can involve a team of specialists to help women who survived early-stage endometrial cancer and have obesity to start a weight management program, possibly including weight loss medications. The study focuses on survivors up to 36 months after their primary treatment, as obesity may have a greater impact on their long-term health than their cancer diagnosis. Participants will be referred to a specialized weight management clinic where they will discuss options such as weight loss medications like GLP-1 agonists, naltrexone/bupropion, orlistat, or phentermine/topiramate, or bariatric surgery. Those who choose weight loss medication will have their routine medical data collected during the study, while those who choose not to use medications will have their weight and health monitored through regular medical visits. During the study, participants will have their health monitored through physical exams, lab tests, and questionnaires over 12 months. Researchers will measure how many start weight loss medications, changes in insulin resistance using HgA1c, quality of life through a cancer therapy assessment, and depression levels. The study also aims to learn why patients decide to start or avoid weight loss medications, with total participation lasting at least one year.
CONDITIONS
Brief Title
Weight Loss Management in Endometrial Cancer Survivors
Who Can Participate
Age: 18Years +
FEMALE
Eligibility Criteria
You may qualify if you...
- 18 years old or older
- ECOG performance status 0 to 2
- Body mass index (BMI) of 30 kg/m2 or greater
- Completed surgical staging with no evidence of remaining disease
- Diagnosed with endometrioid endometrial adenocarcinoma, p53 wild type
- Stage 1 endometrial cancer
- Undergoing active surveillance with or without brachytherapy
You will not qualify if you...
- Unable to participate in behavior-based weight loss
- History of stroke, heart attack, end-stage liver disease, or end-stage kidney disease within the last 6 months
- Currently taking a GLP-1 agonist medication
- Currently using insulin
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
1
2
3
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Weight Management Intervention
Duration - Up to 12 months
Participants meet with a weight management specialist to discuss weight loss options including medications or bariatric surgery, or have their weight recorded during routine medical visits if not on medications.
Visits occur during routine cancer surveillance or weight management appointments
Trial Site Locations
Total: 1 location
1
University of Kansas Medical Center
Kansas City, Kansas, United States, 66160
Actively Recruiting
Loading map...
Research Team
P
Principal Investigator
C
Co-investigator
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Published Research Related To This Trial
2022 American Society of Metabolic and Bariatric Surgery (ASMBS) and International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO) Indications for Metabolic and Bariatric Surgery.
Dan Eisenberg, Scott A Shikora, Edo Aarts...
https://pubmed.ncbi.nlm.nih.gov/36336720Phentermine/Topiramate extended-release capsules (qsymia) for weight loss.
David J Lonneman, Jose A Rey, Brian D McKee
https://pubmed.ncbi.nlm.nih.gov/24222976Evaluation of efficacy and safety of orlistat in obese patients.
Suyog S Jain, Sunita J Ramanand, Jaiprakash B Ramanand...
https://pubmed.ncbi.nlm.nih.gov/21731866Safety and efficacy of naltrexone for weight loss in adult patients - a systematic review.
Agnieszka Kulak-Bejda, Grzegorz Bejda, Napoleon Waszkiewicz
https://pubmed.ncbi.nlm.nih.gov/34336024Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action.
John R Ussher, Daniel J Drucker
https://pubmed.ncbi.nlm.nih.gov/36977782Efficacy and safety of semaglutide on weight loss in obese or overweight patients without diabetes: A systematic review and meta-analysis of randomized controlled trials.
Xueqin Gao, Xiaoli Hua, Xu Wang...
https://pubmed.ncbi.nlm.nih.gov/36188627Interventions for weight reduction in obesity to improve survival in women with endometrial cancer.
Heather Agnew, Sarah Kitson, Emma J Crosbie
https://pubmed.ncbi.nlm.nih.gov/36971688Adiposity, mediating biomarkers and risk of colon cancer in the European prospective investigation into cancer and nutrition study.
Krasimira Aleksandrova, Dagmar Drogan, Heiner Boeing...
https://pubmed.ncbi.nlm.nih.gov/23824948